{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-004874","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.090693+00:00","generated_at":"2026-06-24T17:16:45.784258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PharmaCyte Biotech reports FY2022 net loss of $4.2M; cash at $85.4M; authorizes $10M buyback","bullets":["Cash and cash equivalents of $85.4M as of April 30, 2022; no debt mentioned.","Net loss of ~$4.2M ($0.27 per share) compared to net loss of $3.6M ($2.45 per share) in prior year.","Operating expenses increased to ~$4.4M from $3.6M, mainly due to Nasdaq listing and $90M capital raises.","Board authorized up to $10M share repurchase program, to begin after release of preliminary results.","CEO says company expects to begin two-phase pig study, the last major FDA requirement for phase 2b LAPC trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-004874","json":"https://secwatch.observer/filing/0001683168-22-004874.json","markdown":"https://secwatch.observer/filing/0001683168-22-004874.md","text":"https://secwatch.observer/filing/0001683168-22-004874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822004874/0001683168-22-004874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822004874/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:16:45.784258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}